Mohammad Razaq, MD
Basic profileMohammad Razaq is an Oncology physician affiliated with University of Oklahoma Health Sciences Center. OpenAlex indexes 39 publications with 1,674 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
60 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year202516 payments$1,098
- Celgene CorporationProgram year20252 payments$433
- SHIELD THERAPEUTICS INCProgram year20254 payments$156
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
38.5%Aromatase Inhibitor19.6%Letrozole78%Anastrozole22%Part D<11 patientsKinase inhibitor8%Ibrance32%Cabometyx25%Verzenio25%Jakafi19%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
22.9%Corticosteroid7.8%Prednisone100%Part D≥25 patientsSerotonin-3 Receptor Antagonist6.7%Ondansetron Odt100%Part D≥37 patients+ 3 more classes in this area
Nervous system
8.1%Opioid Agonist2.6%Oxycodone-Acetaminophen100%Part D<11 patientsGabapentinoids2%Gabapentin100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Sunny Po, MD
University of Oklahoma Health Sciences Center
Stavros Stavrakis, MD
University of Oklahoma Health Sciences Center
Raymond Siatkowski, MD
University of Oklahoma Health Sciences Center
Tammy Yanovitch, MD
University of Oklahoma Health Sciences Center
Carl June, MD
University of Pennsylvania
Stuart Orkin, MD
Harvard Medical School
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”